Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

Botta, Cirino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.309
EU - Europa 3.278
AS - Asia 2.713
SA - Sud America 440
AF - Africa 78
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.832
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.177
SG - Singapore 1.150
RU - Federazione Russa 1.018
IT - Italia 1.010
CN - Cina 504
BR - Brasile 339
HK - Hong Kong 318
VN - Vietnam 301
PL - Polonia 241
FR - Francia 189
DE - Germania 171
GB - Regno Unito 146
FI - Finlandia 136
JP - Giappone 93
CA - Canada 86
BD - Bangladesh 75
IE - Irlanda 68
IN - India 62
NL - Olanda 60
AT - Austria 49
AR - Argentina 42
TR - Turchia 35
ES - Italia 32
IQ - Iraq 32
MX - Messico 30
SE - Svezia 24
UA - Ucraina 22
UZ - Uzbekistan 22
EE - Estonia 20
KR - Corea 18
ZA - Sudafrica 18
BE - Belgio 15
CL - Cile 14
EC - Ecuador 13
VE - Venezuela 13
CH - Svizzera 12
MY - Malesia 12
PK - Pakistan 12
EG - Egitto 10
CZ - Repubblica Ceca 9
ID - Indonesia 9
MA - Marocco 9
AE - Emirati Arabi Uniti 8
CI - Costa d'Avorio 8
KE - Kenya 8
CO - Colombia 7
DZ - Algeria 7
JO - Giordania 7
PH - Filippine 7
AL - Albania 6
CR - Costa Rica 6
GR - Grecia 6
PY - Paraguay 6
RO - Romania 6
TN - Tunisia 6
AM - Armenia 5
AU - Australia 5
HU - Ungheria 5
KG - Kirghizistan 5
LT - Lituania 5
NZ - Nuova Zelanda 5
AZ - Azerbaigian 4
IL - Israele 4
RS - Serbia 4
SA - Arabia Saudita 4
TH - Thailandia 4
UY - Uruguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BY - Bielorussia 3
ET - Etiopia 3
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
AO - Angola 2
GT - Guatemala 2
IR - Iran 2
KH - Cambogia 2
LK - Sri Lanka 2
MD - Moldavia 2
ME - Montenegro 2
MM - Myanmar 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AI - Anguilla 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
IM - Isola di Man 1
JM - Giamaica 1
KZ - Kazakistan 1
Totale 10.818
Salva come PNG Salva come JPEG
Città #
Singapore 717
Ashburn 601
San Jose 451
Chandler 375
Hong Kong 287
Fairfield 276
Zgierz 223
Moscow 186
Palermo 143
Beijing 128
Council Bluffs 126
Medford 122
Wilmington 117
Dallas 115
Altamura 114
Lauterbourg 106
Los Angeles 105
Helsinki 95
Tokyo 88
Ho Chi Minh City 86
Milan 86
Princeton 79
Hanoi 77
Lawrence 77
Cambridge 76
New York 73
Houston 72
San Diego 66
Dublin 65
Santa Clara 65
Rome 52
Hefei 45
São Paulo 45
Woodbridge 45
Toronto 42
Buffalo 41
Seattle 39
London 38
Chicago 37
Frankfurt am Main 34
Nuremberg 34
The Dalles 31
Lappeenranta 30
Ann Arbor 29
Paris 25
Montreal 24
Vienna 23
Shanghai 22
Naples 21
Denver 20
Orem 20
Bari 19
Poplar 19
Tallinn 19
Atlanta 18
Phoenix 18
Catania 17
Florence 16
Stockholm 16
Warsaw 16
Brooklyn 15
Haiphong 15
Messina 15
Brussels 14
Da Nang 14
Indianapolis 14
Munich 14
Tashkent 14
Boardman 13
Chennai 13
Mumbai 13
Porto Alegre 13
Amsterdam 12
Ankara 12
Kilburn 12
Turin 12
Bologna 11
Johannesburg 11
Redondo Beach 11
Saint Petersburg 11
Salt Lake City 11
Turku 11
Baghdad 10
Buenos Aires 10
Ludwigshafen am Rhein 10
Mexico City 10
Rio de Janeiro 10
Noto 9
San Paolo di Civitate 9
Vicenza 9
Abbiategrasso 8
Abidjan 8
Guangzhou 8
Piscataway 8
San Francisco 8
West Jordan 8
Amman 7
Belo Horizonte 7
Düsseldorf 7
Edinburgh 7
Totale 6.486
Salva come PNG Salva come JPEG
Nome #
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation 220
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 190
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 184
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 175
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma 168
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 152
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 151
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 149
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 148
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing 145
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 139
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 139
Integrated Multi-Omic Profiling of Immune, Soluble, and Microbial Signatures Identifies Predictors of Multiple Myeloma Evolution 137
Multi-Omic Profiling of NK Cell Dysfunction and Tumor Immune Escape in Multiple Myeloma Evolution 134
Mapping Cell-Cell Communication Dynamics Across the Spectrum of Multiple Myeloma Evolution Using Single-Cell Transcriptomics 133
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? 129
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 129
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing 128
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 127
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant eligible newly diagnosed multiple myeloma: a multicentre real-world experience 127
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 126
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells 123
BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with Natural Killer cell features 123
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma 122
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 122
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 121
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 121
Deciphering the Interplay of Immune Alterations and Microbiome Changes Along Multiple Myeloma Evolution From Premalignant Conditions 119
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 118
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 118
Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients 116
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma 116
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 116
High TIM-3 Expression May Contribute to the Functional Impairment of Bone Marrow and Circulating Gamma Delta T Lymphocytes during the Progression of Multiple Myeloma 116
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different? 114
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 112
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities 111
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 109
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 108
Immunologic characterization of COVID-19 patients with hematological cancer 106
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 105
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 104
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 103
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma 101
AURKA targeting: a NEAT approach to halt myeloma 100
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 100
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 99
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 98
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 97
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 96
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 95
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 95
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma 94
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 94
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma 92
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 92
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates 91
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) 91
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? 91
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm 90
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 90
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 90
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes 88
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 87
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 86
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer 86
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 85
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 85
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials 84
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 84
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 83
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 82
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report 82
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response 82
Immunotherapy of colorectal cancer: New perspectives after a long path 82
POSTER: MM-055 Identification of CD320, CD92, and CD267 as Potential Novel Therapeutic Targets for CAR-T Therapy in Multiple Myeloma 80
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 80
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer 80
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 80
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma 80
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 80
Mouse models of multiple myeloma: Technologic platforms and perspectives 80
miR-22 suppresses DNA ligase III addiction in multiple myeloma 80
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 80
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma 79
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 78
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination 77
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients 75
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients 74
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 74
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 74
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 74
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 73
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 73
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation 73
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 73
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 73
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients 72
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells 71
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 70
Totale 10.448
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.048
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021761 0 0 0 0 0 0 0 0 0 0 19 742
2021/2022912 56 131 28 27 23 76 44 43 100 153 61 170
2022/20231.378 109 247 94 112 146 182 21 137 152 18 118 42
2023/2024766 46 116 57 122 68 75 69 56 23 30 10 94
2024/20251.792 55 148 96 164 64 108 137 128 169 178 169 376
2025/20265.952 313 189 334 545 679 869 930 724 705 413 251 0
Totale 11.574